Trastuzumab, tyrosine kinase inhibitors (lapatinib, afatinib, pyrotinib), P13K/serine, threonine kinase/mTOR (PI3K/AKT/mTOR), and blocking drugs (e.g., trastuzumab, everolimus, paclitaxel) are regarded as options for the treatment of HER2-positive BC [11,12]. The gene discussed is ERBB2; the disease is breast cancer.